Cymab ApS: Financial statements 2021
CVR: 39859173
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Cymab ApS (CVR 39859173) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -566,735 and a net result of DKK -942,533 compared with DKK -955,753 the year before. Equity in the 2021 report amounted to DKK -3,901,796. The company had 1 employee in the financial year.
- Gross Profit
- DKK -566,735
- Profit/Loss
- DKK -942,533
- Equity
- DKK -3,901,796
- Total Assets
- DKK 382,636
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -567K | -943K | -3.9M | 1 |
| 2020 | 0 | -1.1M | -956K | -3M | - |
Official annual report
Find more companies like Cymab ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
Cymab ApS has published its annual report for 2020. Revenue came to DKK 0, and the net result was DKK -955,753.
As of May 21, 2021, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of May 21, 2021, Thomas Dal Stenfeldt Batchelor has joined the board of directors of Cymab ApS.
As of May 21, 2021, Hans Heugh Wandall is registered as adm. dir. of Cymab ApS.
As of May 20, 2021, Hans Heugh Wandall has left the board of directors of Cymab ApS.
As of May 20, 2021, Thomas Dal Stenfeldt Batchelor has left the board of directors of Cymab ApS.
About Cymab ApS
Cymab ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab ApS. The management consists of Johan Henrik Faber. The board consists of Hans Heugh Wandall (chair), Johan Henrik Faber, Mads Nikolaj Behrndt-Eriksen and Søren Erik Bjørn. The company is owned by Ebumab Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK -5,463,240 and a net result of DKK -7,576,022 compared with DKK -4,627,624 the year before. Equity in the 2025 report amounted to DKK -20,227,476.